発表論文一覧

（*: corresponding author）

Original Articles

1. Iwata T, *Kishikawa T, Seimiya T, Notoya G, Suzuki T, Shibata C, Miyakawa Y, Odawara N, Funato K, Tanaka E, Yamagami M, Sekiba K, Otsuka M, Koike K, Fujishiro M. Satellite double-stranded RNA induces mesenchymal transition in pancreatic cancer by regulating alternative splicing. J Biol Chem. 2024 Feb 10:105742.

2. Miyakawa Y, *Otsuka M, Shibata C, Seimiya T, Yamamoto K, Ishibashi R, Kishikawa T, Tanaka E, Isagawa T, Takeda N, Kamio N, Imai K, Fujishiro M. Gut Bacteria-derived Membrane Vesicles Induce Colonic Dysplasia by Inducing DNA Damage in Colon Epithelial Cells. Cell Mol Gastroenterol Hepatol. 2024 Feb 1:S2352-345X(24)00010-9.

3. Seimiya T, Suzuki T, Iwata T, Kishikawa T, Sekiba K, Shibata C, Ishigaki K, Fujiwara H, Oyama H, Kanai S, Sato T, Nakai Y, Ishibashi R, Moriyama M, Nakagawa R, Ijichi H, *Otsuka M, Koike K. Combination of serum human satellite RNA and miR-21-5p levels as a biomarker for pancreatic cancer. iScience. 2023;26(2):106021

4. Funato K, Miyake N, Sekiba K, Miyakawa Y, Seimiya T, Shibata C, Kishikawa T, *Otsuka M. Cabozantinib inhibits HBV-RNA transcription by decreasing STAT3 binding to the enhancer region of cccDNA. Hepatol Commun. 2023; 8;7(11):e0313.

5. Shibata C, Otsuka M, Shimizu T, Seimiya T, Kishikawa T, Aoki T, Fujishiro M. Extracellular vesicle‑mediated RNA editing may underlie the heterogeneity and spread of hepatocellular carcinoma in human tissue and in vitro. Oncol Rep. 2023;50(5):194.

6. Kanai S, *Fujiwara H, Mizuno S, Kishikawa T, Nakatsuka T, Hamada T, Tanaka M, Arita J, Nakai Y, Isayama H, Kasuga M, Tateishi R, Tateishi K, Ushiku T, Hasegawa K, Koike K, Fujishiro M. Increased expression of TNFRSF14 and LIGHT in biliary epithelial cells of patients with primary sclerosing cholangitis. Dig Liver Dis. 2024;56(2):305-311.

7. Kato H, *Tateishi K, Iwadate D, Yamamoto K, Fujiwara H, Nakatsuka T, Kudo Y, Hayakawa Y, Ijichi H, Otsuka M, Kishikawa T, Takahashi R, Miyabayashi K, Nakai Y, Hirata Y, Toyoda A, Morishita S, Fujishiro M. HNF1B-driven three-dimensional chromatin structure for molecular classification in pancreatic cancers. Cancer Sci. 2023;114(4):1672-1685.

8. Shibata C, *Otsuka M, Seimiya T, Kishikawa T, Ishigaki K, Fujishiro M. Lipolysis by pancreatic cancer-derived extracellular vesicles in cancer-associated cachexia via specific integrins. Clin Transl Med. 2022;12(11):e1089.

9. Shibata C, *Otsuka M, Seimiya T, Ishigaki K, Miyakawa Y, Kishikawa T, Fujishiro M. Smaller extracellular vesicles are released from pancreatic cancer cells by the alteration of the lipid composition under low glucose conditions. Biochem Biophys Res Commun. 2022;637:314-321.

10. Kawamura S, Matsushita Y, Kurosaki S, Tange M, Fujiwara N, Hayata Y, Hayakawa Y, Suzuki N, Hata M, Tsuboi M, Kishikawa T, Kinoshita H, Nakatsuka T, Sato M, Kudo Y, Hoshida Y, Umemura A, Eguchi A, Ikenoue T, Hirata Y, Uesugi M, Tateishi R, Tateishi K, Fujishiro M, Koike K, *Nakagawa H. Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis. J Clin Invest. 2022;e151895.

11. Funato K, *Otsuka M, Sekiba K, Miyakawa Y, Seimiya T, Shibata C, Kishikawa T, Fujishiro M. Hepatitis B virus-associated hepatocellular carcinoma with Smc5/6 complex deficiency is susceptible to PARP inhibitors. Biochem Biophys Res Commun. 2022;607:89-95.

12. Suzuki T, Kishikawa T, Sato T, Takeda N, Sugiura Y, Seimiya T, Sekiba K, Ohno M, Iwata T, Ishibashi R, *Otsuka M, Koike K. Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells. Cancer Gene Ther. 2022;29:505–518

13. Nakatsuka T, *Nakagawa H, Hayata Y, Wake T, Yamada T, Nishibatake Kinoshita M, Nakagomi R, Sato M, Minami T, Uchino K, Enooku K, Kudo Y, Tanaka Y, Kishikawa T, Otsuka M, Tateishi R, Koike K. Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma. J Gastroenterol. 2021;56(5):456-469. 

14. Kato H, *Tateishi K, Fujiwara H, Nakatsuka T, Yamamoto K, Kudo Y, Hayakawa Y, Nakagawa H, Tanaka Y, Ijichi H, Otsuka M, Iwadate D, Oyama H, Kanai S, Noguchi K, Suzuki T, Sato T, Hakuta R, Ishigaki K, Saito K, Saito T, Takahara N, Kishikawa T, Hamada T, Takahashi R, Miyabayashi K, Mizuno S, Kogure H, Nakai Y, Hirata Y, Toyoda A, Ichikawa K, Qu W, Morishita S, Arita J, Tanaka M, Ushiku T, Hasegawa K, Fujishiro M, Koike K. MNX1-HNF1B axis is indispensable for intraductal papillary mucinous neoplasm lineages. Gastroenterology 2021;S0016-5085(21):04090-7.

15. Kishikawa T, Higuchi H, Wang L, Panch N, Maymi V, Best S, Lee S, Notoya G, Toker A, Matesic L, Wulf G, Wei W, Otsuka M, Koike K, Clohessy J, Lee YR, *Pandolfi PP. WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models. J Clin Invest. 2021;131(24):e140436. 

16. Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, Otsuka M, Tamaki N, Kogiso T, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol. 2021;56(11):951-963. 

17. Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, Otsuka M, Tamaki N, Kogiso T, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Hepatol Res. 2021 Oct;51(10):1013-1025.  

18. Sekiba K, #Otsuka M, Funato K, Miyakawa Y, Tanaka E, Seimiya T, Yamagami M, Tsutsumi T, Okushin K, Miyakawa K, Ryo A, Koike K. Hepatitis B Virus X Protein-Induced Degradation of Smc5/6 Complex Impairs Homologous Recombination-Mediated Repair of Damaged DNA. J Hepatol. 2022 Jan;76(1):53-62.   

19. Miyakawa Y, #Otsuka M, Sekiba K, Funato K, Koike K. hzVSF inhibits HBV infection via targeting viral cell entry. Heliyon. 2021;7(7):e07586.   

20. Suzuki T, Kishikawa T, Sato T, Takeda N, Sugiura Y, Sekiba K, Ohno M, Iwata T, Ishibashi R, #Otsuka M, Koike K. Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells. Cancer Gene Ther. in press.

21. Nakatsuka T, Nakagawa H, Hayata Y, Wake T, Yamada T, Nishibatake Kinoshita M, Nakagomi R, Sato M, Minami T, Uchino K, Enooku K, Kudo Y, Tanaka Y, Kishikawa T, Otsuka M, Tateishi R, Koike K. Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma. J Gastroenterol. In press.

22. Minami T, Tateishi R, Fujiwara N, Nakagomi R, Nakatsuka T, Sato M, Uchino K, Enooku K, Nakagawa H, Fujinaga H, Izumiya M, Hanajiri K, Asaoka Y, Kondo Y, Tanaka Y, Otsuka M, Ohki T,  Arai M, Tanaka A, Yasuda K, Miura H, Ogata I, Kamoshida T, Inoue K, Koike Y, Akamatsu M, Mitsui H, Fujie H, Ogura K, Yoshida H, Wada T, Kurai K, Maekawa H, Obi S, Teratani T, Masaki N, Nagashima K, Ishikawa T, Kato N, Moriya K, Yotsuyanagi H, Koike K. Impact of obesity and heavy alcohol consumption on hepatocellular carcinoma development after HCV eradication with antivirals. Liver Cancer. in press.

23. Kato H, Tateishi K, Fujiwara H, Ijichi H, Yamamoto K, Nakatsuka T, Kakiuchi M, Sano M, Kudo Y, Hayakawa Y, Nakagawa H, Tanaka Y, Otsuka M, Hirata Y, Tachibana M, Shinkai Y, Koike K. Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis. Cancer Genomics Proteomics. 2020 Nov-Dec;17(6):695-705.

24. Sekiba K, #Otsuka M, Seimiya T, Tanaka E, Funato K, Miyakawa Y, Koike K. The fatty-acid amide hydrolase inhibitor URB597 inhibits MICA/B shedding. Sci Rep. 2020 Sep 23;10(1):15556. 

25. Seimiya T, #Otsuka M, Iwata T, Tanaka E, Sekiba K, Shibata C, Moriyama M, Nakagawa R, Maruyama R, Koike K. Aberrant expression of a novel circular RNA in pancreatic cancer. J Human Genet. 2021 Feb;66(2):181-191. doi: 10.1038/s10038-020-00826-5. 

26. Kakizaki M, Yamamoto Y, Otsuka M, Kitamura K, Ito M, Kawai H, Muramatsu M, Kagawa T  and Kotani A. Extracellular vesicles secreted by HBV-infected cells modulate HBV persistence in hydrodynamic HBV transfection mouse model. J Biol Chem. In press.

27. Ochi M, #Otsuka M, Maruyama R, Koike K. HBx increases EGFR expression by inhibiting miR129–5p function. Biochem Biophys Res Commun. 2020;529(2):198-203.

28. Wake T, Tateishi R, Fukumoto T, Nakagomi R, Kinoshita MN, Nakatsuka T, Sato M, Minami T, Uchino K, Enooku K, Nakagawa H, Fujinaga H, Asaoka Y, Tanaka Y, Otsuka M, Koike K.Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume. PLoS ONE. 2020 Apr 20;15(4):e0231836.

29. Sekiba K, Otsuka M, Koike K. Identifying Inhibitors of the HBx–DDB1 Interaction Using a Split Luciferase Assay System. J Vis Exp. 2019 Dec 21;(154)

30. Ishibashi R, Yoshida S, Odawara N, Kishikawa T, Kondo R, Nakada A, Hakuta R, Takahara N, Tanaka E, Sekiba K, Seimiya T, Ohnaga T, #Otsuka M, Koike K. Detection of circulating colorectal cancer cells by a custom microfluid system before and after the endoscopic metallic stent placement. Oncol Lett.  2019 Dec;18(6):6397-6404. 

31. Tanaka E, Miyakawa Y, Kishikawa T, Seimiya T, Iwata T, Funato K, Odawara N, Sekiba K, Yamagami M, Suzuki T, Ishibashi R, #Otsuka M, Koike K. Expression of circular RNA CDR1-AS in colon cancer cells increases cell surface PD-L1 protein levels. Oncol Rep. 

32. Sekiba K, #Otsuka M, Ohno M, Yamagami M, Kishikawa T, Seimiya T, Suzuki T, Tanaka E, Ishibashi R, Funato K, and Koike K. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus. Hepatology  2019 May;69(5):1903-1915.

33. Sekiba K, #Otsuka M, Ohno M, Yamagami M, Kishikawa T, Suzuki T, Ishibashi R, Seimiya T, Tanaka E, Koike K.Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx–DDB1 interaction. Cell Mol Gastroenterol Hepatol. 2019;7(2):297-312.

34. Nakagomi R, Tateishi R, Masuzaki R, Soroida Y, Iwai T, Kondo M, Fujiwara N, Sato M, Minami T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Tanaka Y, Otsuka M, Kato N, Moriya K, Ikeda H, Koike K. Liver stiffness measurements in chronic hepatitis C: treatment evaluation and risk assessment J Gastroenterol Hepatol. 2019 May;34(5):921-928.

35. Yamagami M, #Otsuka M, Kishikawa T, Sekiba K, Seimiya T, Tanaka E, Suzuki T,  Ishibashi R, Ohno M, Koike K. ISGF3 with reduced phosphorylation is associated with constitutive expression of interferon-induced genes in aging cells. npj Aging Mech Dis. 2018;4:11.

36. Kishikawa T, #Otsuka M, Suzuki T, Seimiya T, Sekiba K, Ishibashi R, Tanaka E, Ohno M, Yamagami M, Koike K. Satellite RNA Increases DNA Damage and Accelerates Tumor Formation in Mouse Models of Pancreatic Cancer Mol Cancer Res. 2018 Aug;16(8):1255-1262.

37. Sekiba K, #Otsuka M, Ohno M, Kishikawa T, Yamagami M, Suzuki T, Ishibashi R, Seimiya T, Tanaka E, Koike K. DHX9 regulates production of hepatitis B virus-derived circular RNA and viral protein levels. Oncotarget 2018; 9(39):20953-20964.

38. Fujiwara N, Nakagawa H, Enooku K, Kudo Y, Hayata Y, Nakatsuka T, Tanaka Y, Tateishi R, Hikiba Y, Misumi K, Tanaka M, Hayashi A, Shibahara J, Fukayama M, Arita J, Hasegawa K, Hirschfield H, Hoshida Y, Hirata Y, Otsuka M, Tateishi K, Koike K. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut. 2018 Aug;67(8):1493-1504. 

39. Nakatsuka T, Tateishi K, Kudo Y, Yamamoto K, Nakagawa H, Fujiwara H, Takahashi R, Miyabayashi K, Asaoka Y, Tanaka Y, Ijichi H, Hirata Y, Otsuka M, Kato M, Sakai J, Tachibana M, Aburatani H, Shinkai Y, Koike K. Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation. Oncogene. 2017 Nov 9;36(45):6262-6271.

40. Takata A, #Otsuka M, Kishikawa T, Yamagami M, Ishibashi R, Sekiba K, Suzuki T, Ohno M, Yamashita Y, Abe T, Masuzaki R, Ikenoue T, Koike K. RASAL1 is a potent regulator of hepatic stellate cell activity and liver fibrosis Oncotarget 2017 May 4;8(39):64840-64852. 

41. Nakagawa H, Suzuki N, Hirata Y,Hikiba Y, Hayakawa Y, Kinoshita H, Ihara S, Uchino K, Nishikawa Y, Ijichi H, Otsuka M, Arita J, Sakamoto Y, Hasegawa K, Kokudo N, Tateishi K, Koike K. Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands. Proc Natl Acad Sci U S A. 2017

42. Nakatsuka T, Tateishi K, Kudo Y, Yamamoto K, Nakagawa H, Fujiwara H, Takahashi R, Miyabayashi K, Asaoka Y, Tanaka Y, Ijichi H, Hirata Y, Otsuka M, Kato M, Sakai J, Tachibana M, Aburatani H, Shinkai Y, Koike K. Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation. Oncogene.Takata A, #Otsuka M, Kishikawa T, Yamagami M, Ishibashi R, Sekiba K, Suzuki T, Ohno M, Yamashita Y, Abe T, Masuzaki R, Ikenoue T, Koike K. RASAL1 is a potent regulator of hepatic stellate cell activity and liver fibrosis Oncotarget 2017 in press

43. Sekiba K, Yamagami M, #Otsuka M, Suzuki T, Kishikawa T, Ishibashi R, Ohno M, Sato M, Koike K. Transcriptional activation of the MICA gene with an engineered CRISPR-Cas9 system. Biochem Biophys Res Commun. 2017 Apr 29;486(2):521-525.

44. Yoshikawa T, Wu JF, #Otsuka M, Kishikawa T, Suzuki N, Takata A, Ohno M, Ishibashi R, Yamagami M, Nakagawa R, Kato N, Miyazawa M, Han J, Koike K. Repression of miRNA Function Mediates Inflammation-associated Colon Tumorigenesis. Gastroenterology2017 Feb;152(3):631-643.

45. Kishikawa T, #Otsuka M, Yoshikawa T, Ohno M, Yamamoto K, Yamamoto N, Kotani A, Koike K. Quantitation of circulating satellite RNAs in pancreatic cancer patients. JCI Insight 2016;1(8):e86646.

46. Takata A, #Otsuka M, Ohno M, Kishikawa T, Yoshikawa T, Koike K. Mutual antagonism between hepatitis B viral mRNA and host microRNA let-7. Sci Rep. 2016;6:23237.

47. Kishikawa T, #Otsuka M, Ohno M, Yoshikawa T, Sato M, Koike K. Development of a Screening Method to Identify Regulators of MICA Shedding. Biochem Biophys Res Commun. 2015;465(4):764-8.

48. Kang Y, Bang BR, Han KH, Hong L, Shim EJ, Ma J, Lerner R, Otsuka M. Regulation of NKT cell-mediated immune responses to tumors and liver inflammation by mitochondrial PGAM5−Drp1 signaling. Nat Commun. 2015;6:8371.

49. Yoshikawa T, Wu JF, #Otsuka M, Kishikawa T, Ohno M, Shibata C, Takata A, Han F, Kang YJ, Chen CY, Shyu AB, Han J, Koike K. ROCK inhibition enhances microRNA function by promoting deadenylation of targeted mRNAs via increasing PAIP2 expression. Nucleic Acids Res. 2015;43(15):7577-89.

50. Kang YJ, Bang BR, Otsuka M, Otsu K. Tissue-specific regulation of p38α-mediated inflammation in ConA-induced acute liver damage. J Immunol. 2015;194(10):4759-66.

51. Kishikawa T, #Otsuka M, Poh Seng T,  Ohno M, Sun X, Yoshikawa T, Shibata C, Takata A, Kojima K, TakehanaK, Ohishi M, Ota S, Noyama T, Kondo Y, Sato M, Soga T, Hoshida Y, Koike K. Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine. Oncotarget 2015;6(10):8339-52.

52. Yamamoto K, Tateishi K, Kudo Y, Sato T, Yamamoto S, Miyabayashi K, Asaoka Y, Ijichi H, Hirata Y, Otsuka M, Nakai Y, Isayama H, Ikenoue T, Kurokawa M, Fukayama M, Kokudo N, Omata M, Koike K. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα. Carcinogenesis. 2014;35(11):2404-14.

53. Ohno M*, #Otsuka M*, Kishikawa T, Shibata C, Yoshikawa T, Takata A, Muroyama R, Kowatari N, Sato M, Kato N, Kuroda S, Koike K (*; equal contribution). Specific delivery of microRNA93 into HBV-replicating hepatocytes downregulates protein expression of liver cancer susceptible gene MICA. Oncotarget 2014;5(14):5581-90.

54. Shibata C, Ohno M, #Otsuka M, Kishikawa T, Goto K, Muroyama R, Kato N, Yoshikawa T, Takata A, Koike K. The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels. Virology 2014;462-463:42-8.

55. Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H, Omata M, Koike K. The Impact of PNPLA3 Polymorphisms on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Virus Infection. Hepatol Res. 2014;44(10):E137-44.

56. Ma J, Bang BR, Lu J, Eun SY, Otsuka M, Croft M, Tobias P, Han J, Takeuchi O, Akira S, Karin M, Yagita H, Kang YJ. The tumor necrosis family member 4-1BBL sustains inflammation by interacting with TLR signaling components during late-phase activation. Sci Signal. 2013;6:ra87.

57. Kishikawa T*, #Otsuka M*, Yoshikawa T, Ohno M, Takata A, Shibata C, Kondo Y, Akanuma M, Yoshida H, Koike K (*, equal contribution). Regulation of the expression of the liver cancer susceptibility gene MICA by microRNAs. Sci Rep. 2013;3:2739.

58. Ohno M, Shibata C, Kishikawa T, Yoshikawa T, Takata A, Kojima K, Akanuma M, Kang YJ, Yoshida H, #Otsuka M, Koike K.  The flavonoid apigenin improves glucose tolerance through inhibition of microRNA maturation in miRNA103 transgenic mice. Sci Rep. 2013;3:2553.

59. Shibata C, Kishikawa T, #Otsuka M, Ohno M, Yoshikawa T, Takata A, Yoshida H, Koike K. Inhibition of microRNA122 decreases SREBP1 expression by modulating suppressor of cytokine signaling 3 expression. Biochem Biophys Res Commun.2013;438(1):230-5.

60. Yoshikawa T, #Otsuka M, Kishikawa T, Takata A, Ohno M, Shibata C, Kang YJ, Yoshida H, Koike K. Unique haploinsufficient role of the microRNA-processing molecule Dicer1 in a murine colitis-associated tumorigenesis model. PLoS ONE 2013;8(9):e71969. 

61. Shim E-J, Bang BR, Kang S-G, Ma J, Otsuka M, Kang J, Stahl M, Han J, Xiao C, Vallance BA, Kang YJ. Activation of p38a in T cells regulates the intestinal host defense against attaching and effacing bacterial infections. J Immunol. 2013;191(5):2764-70.

62. Yamamoto S, Tateishi K, Kudo Y, Yamamoto K, Isagawa T, Nagae G, Nakatsuka T, Asaoka Y, Ijichi H, Hirata Y, Otsuka M, Ikenoue T, Aburatani H, Omata M, Koike K. Histone demethylase KDM4C regulates sphere formation by mediating the crosstalk between Wnt and Notch pathways in colonic cancer cells. Carcinogenesis. 2014 Nov;35(11):2404-14.

63. Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H, Omata M, Koike K. IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. J Gastroenterol. 2013;49(4):748-54.

64. Kogiso T, Nagahara H, Otsuka M, Shiratori K, Dowdy SF. Transdifferentiation of human fibroblasts into hepatocyte-like cells by defined transcriptional factors. Hepatol Int. 2013;7:937-44.

65. Takata A, #Otsuka M, Yoshikawa T, Kishikawa T, Hikiba Y, Obi S, Goto T, Kang Y, Maeda S, Yoshida H, Omata M, Asahara H, Koike K. MiRNA-140 acts as a liver tumor suppressor by controlling NF-kB activity via directly targeting Dnmt1 expression. Hepatology 2013;57(1):162-70.

66. Urabe Y, Ochi H, Kato N, Kumar V, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, Lo PH, Tanikawa C, Omata M, Koike K, Miki D, Abe H, Kamatani N, Toyota J, Kumada H, Kubo M, Chayama K, Nakamura Y, Matsuda K. A genome-wide association study of HCV induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at MHC region. J Hepatol. 2013;58(5):875-82.

67. Yoshikawa T*, Takata A*, #Otsuka M*, Kishikawa T, Kojima K, Yoshida H, Koike K  (*; equal contribution). Silencing of microRNA-122 enhances interferon-a signaling in the liver through regulating SOCS3 promoter methylation. Sci Rep. 2012;2:637.

68. Takata A, #Otsuka M, Yoshikawa T, Kishikawa T, Kudo Y, Goto T, Yoshida H, Koike K. A miRNA machinery component DDX20 controls NF-kB via microRNA-140 function. Biochem Biophys Res Commun. 2012;420(3):564-9.

69. #Otsuka M, Takata A, Yoshikawa T, Kojima K, Kishikawa T, Shibata C, Takekawa M, Yoshida H, Omata M, Koike K. Receptor for activated protein kinase C: requirement for efficient microRNA function and reduced expression in hepatocellular carcinoma. PLoS ONE 2011; 6(9): e24539. doi: 10.1371/journal.pone.0024359

70. Kojima K, Takata A, Vadnais C, #Otsuka M , Yoshikawa T, Akanuma M, Kondo Y, Kang YJ, Kishikawa T, Kato N, Xie Z, Zhang WJ, Yoshida H, Omata M, Nepveu A, Koike K. MicroRNA122 is a key regulator of α-fetoprotein expression and biologically aggressive behavior of hepatocellular carcinoma. Nat Commun. 2011; 2: 338.

71. Takata A, #Otsuka M, Kojima K, Yoshikawa T, Kishikawa T, Yoshida H, Koike K. MicroRNA-22 and microRNA-140 suppress NF-κB activity by regulating the expression of NF-κB coactivators. Biochem Biophys Res Commun. 2011;411(4):826-31.

72. Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, Omata M, Nakagawa H, Koike K, Kamatani N, Kubo M, Nakamura Y, Matsuda K. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet. 2011;43(5):455-8.

73. Takata A, #Otsuka M, Kogiso T, Kojima K, Yoshikawa T, Tateishi R, Kato N, Shiina S, Yoshida H, Omata M, Koike K. Direct differentiation of hepatic cells from human induced pluripotent stem cells using a limited number of cytokines. Hepatol Int.2011;5(4):890-8.

74. Kudo Y, Tanaka Y, Tateishi K, Yamamoto K, Yamamoto S, Mohri D, Isomura Y, Seto M, Nakagawa H, Asaoka Y, Tada M, Ohta M, Ijichi H, Hirata Y, Otsuka M, Ikenoue T, Maeda S, Shiina S, Yoshida H, Nakajima O, Kanai F, Omata M, Koike K. Altered Composition of Fatty Acids Exacerbates Hepatotumorigenesis during Activation of the Phosphatidylinositol 3-kinase Pathway. J Hepatol. 2011:5:890-8.

75. Soga T, Sugimoto M, Honma M, Mori M, Igarashi K, Kashikura K, Ikeda S, Hirayama A, Yamamoto T, Yoshida H, Otsuka M, Tsuji S, Yatomi Y, Sakuragawa T, Watanabe H, Nihei K, Saito T, Kawata S, Suzuki H, Tomita M, Suematsu M. Serum Metabolomics Reveals g-Gutamyl dipeptides as Biomarkers for Discrimination among Different Forms of Liver Disease. J Hepatol. 2011;55(4):896-905.

76. Seto M, Ohta M, Ikenoue T, Sugimoto T, Asaoka Y, Tada M, Mohri D, Kudo Y, Ijichi H, Tateishi K, Otsuka M, Hirata Y, Maeda S, Koike K, Omata M. Reduced expression of RAS protein activator like 1 in gastric cancer. Int J Cancer. 2011;128(6):1293-302.

77. Kang YJ*, Otsuka M*, van den Berg A, Hong L, Huang Z, Wu X, Zhang DW, Vallance BA, Tobias PS, Han J. Epithelial p38a Controls Immune Cell Recruitment in the Colonic Mucosa. PLoS Pathog. 2010 Jun 3;6(6):e1000934. (*; equal contribution)

78. Otsuka M, Kang YJ, Ren J, Jiang H, Wang Y, Omata M, Han J. Distinct effects of p38alpha deletion in myeloid lineage and gut epithelia in mouse models of inflammatory bowel disease. Gastroenterology. 2010;138(4):1255-65.

79. Hayakawa Y, Hirata Y, Nakagawa H, Sakamoto K, Hikiba Y, Otsuka M, Ijichi H, Ikenoue T, Tateishi K, Akanuma M, Ogura K, Yoshida H, Ichijo H, Omata M, Maeda S. Apoptosis Signal-Regulating Kinase 1 regulates colitis and colitis-associated tumorigenesis via innate immune responses. Gastroenterology. 2010 Mar;138(3):1055-67.

80. Mols J, Berg AV, Otsuka M, Zheng M, Chen J, Han J. TNF-alpha stimulation inhibits siRNA-mediated RNA interference through a mechanism involving poly-(A) tail stabilization. Biochim Biophys Acta. 2008;1779(11):712-9.

81. Otsuka M, Zheng M, Hayashi M, Lee JD, Yoshino O, Lin S, Han J. Impaired microRNA processing causes corpus luteum insufficiency and infertility in mice. J Clin Invest. 2008;118(5):1944-1954.

82. Kang YJ, Chen J, Otsuka M, Mols J, Ren S, Wang Y, Han J. Macrophage Deletion of p38{alpha} Partially Impairs Lipopolysaccharide-Induced Cellular Activation. J Immunol.2008;180:5075-82.

83. Dharel N, Kato N, Muroyama R, Taniguchi H, Otsuka M, Wang Y, Jazag A, Shao RX, Chang JH, Adler MK, Kawabe T, Omata M. Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus. Hepatology. 2008;47(4):1136-49.

84. Kang YJ, Kusler B, Otsuka M, Hughes M, Suzuki N, Suzuki S, Yeh WC, Akira S, Han J, Jones PP. Calcineurin Negatively Regulates TLR-Mediated Activation Pathways. J Immunol.2007;179:4598-607.

85. Otsuka M, Jing Q, Georgel P, New L, Chen J, Mols J, Kang YJ, Jiang Z, Du X, Cook  R, Das SC, Pattnaik AK, Beutler B, Han J. Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression. Immunity. 2007;27:123-34.

86. Kang YJ, Kim SO, Shimada S, Otsuka M, Seit-Nebi A, Kwon BS, Watts TH, Han J. Cell surface 4-1BBL mediates sequential signaling pathways 'downstream' of TLR and is required for sustained TNF production in macrophages. Nat Immunol. 2007;8:601-9.

87. Hoshida Y, Moriyama M, Otsuka M, Kato N, Taniguchi H, Shiratori Y, Seki N, Omata M. Gene expressions associated with chemosensitivity in human hepatoma cells. Hepatogastroenterology. 2007;54:489-92.

88. Moriyama M, Kato N, Otsuka M, Shao RX, Taniguchi H, Kawabe T, Omata M. Interferon-beta is activated by hepatitis C virus NS5B and inhibited by NS4A, NS4B, and NS5A. Hepatol Int. 2007 Jun;1(2):302-10.

89. Muroyama R, Kato N, Yoshida H, Otsuka M, Moriyama M, Wang Y, Shao RX, Dharel N, Tanaka Y, Ohta M, Tateishi R, Shiina S, Tatsukawa M, Fukai K, Imazeki F, Yokosuka O, Shiratori Y, Omata M. Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma. J Hepatol. 2006;45:805-12.

90. Shao RX, Kato N, Lin LJ, Muroyama R, Moriyama M, Ikenoue T, Watabe H, Otsuka M, Guleng B, Ohta M, Tanaka Y, Kondo S, Dharel N, Chang JH, Yoshida H, Kawabe T, Omata M. Absence of tyrosine kinase mutations in Japanese colorectal cancer patients. Oncogene. 2006;26:2133-5.  

91. Wang Y, Kato N, Jazag A, Dharel N, Otsuka M, Taniguchi H, Kawabe T, Omata M. Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response. Gastroenterology. 2006;130:883-92.

92. Shibata W, Hirata Y, Yoshida H, Otsuka M, Hoshida Y, Ogura K, Maeda S, Ohmae T, Yanai A, Mitsuno Y, Seki N, Kawabe T, Omata M. NF-kappaB and ERK-signaling pathways contribute to the gene expression induced by cag PAI-positive-Helicobacter pylori infection. World J Gastroenterol. 2005;11:6134-43.

93. Nakai Y, Otsuka M, Hoshida Y, Tada M, Komatsu Y, Kawabe T, Omata M. Identifying genes with differential expression in gemcitabine-resistant pancreatic cancer cells using comprehensive transcriptome analysis. Oncol Rep. 2005;14:1263-7.

94. Kato N, Ji G, Wang Y, Baba M, Hoshida Y, Otsuka M, Tnaiguchi H, Moriyama M, Dharel N, Goto T, Shao R-X, Matsuura T, Ishii K, Shiina S, Kawabe T, Muramatsu M, Omata M. Large-scale Search of SNPs for Hepatocellular Carcinoma Susceptibility Genes in Patients with Hepatitis C. Hepatology. 2005;42:846-853.

95. Hoshida Y, Kato N, Yoshida H, Wang Y, Tanaka M, Goto T, Otsuka M, Taniguchi H, Moriyama M, Imazeki F, Yokosuka O, Kawabe T, Shiratori Y, Omata M. Hepatitis C virus core protein and hepatitis activity are associated through transactivation of interleukin-8. J Infect Dis. 2005;192:266-75.

96. Shao R-X, Otuska M, Kato N, Chang J-H, Muroyama R, Taniguchi H, Moriyama M, Wang Y, Kawabe T, Omata M. No mutations in the tyrosine kinases of human hepatic, pancreatic, and gastric cancer cell lines. J Gastroenterol. 2005;40:918.

97. Otsuka M, Kato N, Moriyama M, Taniguchi H, Wang Y, Dharel N, Kawabe T, and Omata M. Interaction between the HCV NS3 Protein and the Host TBK1 Prote in Leads to Inhibition of Cellular Antiviral Responses. Hepatology. 2005;41:1004-1012.

98. Otsuka M, Kato N, Ichimura T, Abe S, Tanaka Y, Taniguchi H, Hoshida Y, Moriyama M, Wang Y, Shao R-X, Narayan D, Muroyama R, Kanai F, Kawabe T, Isobe T, Omata M. Vitamin K2 binds 17b-hydroxysteroid dehydrogenase 4 and modulates estrogen metabolism. Life Sciences. 2005; 76:2473-82.

99. Shao R-X, Otsuka M, Kato N, Taniguchi H, Hoshida Y, Moriyama M, Kawabe T, Omata M. Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways. Gastroenterology. 2005;128:86-95.

100. Qui Y, Hoshida Y, Kato N, Moriyama M, Otsuka M, Taniguchi H, Kawabe T, Omata M. A simple cdombination of serum type IV collagen and prothrombin time to diagnose cirrhosis in patients with chronic active hepatitis C. Hepatol Res. 2004;30:214-220.

101. Shao R-X, Hoshida Y, Otsuka M, Kato N, Tateishi R, Teratani T, Shiina S, Taniguchi H, Moriyama M, Kawabe T, Omata M. Hepatic gene expression profiles associated with fibrosis progression and hepatocarcinogenesis in hepatitis C patients.  World J Gastroenterol. 2005;11:1995-9.

102. Moriyama M, Hoshida Y, Kato N, Otuska M, Yoshida H, Kawabe T, Omata M. Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy. Int J Oncol. 2004;25:1279-87.

103. Otsuka M, Kato N, Shao R-X, Hoshida Y, Ijichi H, Koike Y, Taniguchi H, Moriyama M, Shiratori Y, Kawabe T, Omata M. Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via Protein Kinase A activation. Hepatology. 2004;40:243-251.

104. Wang Y, Kato N, Hoshida Y, Otsuka M, Taniguchi H, Moriyama M, Shiina S, Kawabe T, Ito YM, Omata M. UDP-Glucuronosyltransferase 1A7 Genetic Polymorphisms Are Associated withHepatocellular Carcinoma in Japanese Patients with Hepatitis C Virus Infection. Clin Cancer Res. 2004;10:2441-2446.

105. Taniguchi H, Kato N, Otsuka M, Goto T, Yoshida H, Shiratori Y, Omata M. Hepatitis C virus core protein upregulates transforming growth factor-beta1 transcription.J Med Virol.2004;72:52-9.

106. Sacco R, Tsutsumi T, Suzuki R, Otsuka M, Aizaki H, Sakamoto S, Matsuda M, Seki N, Matsuura Y, Miyamura T, Suzuki T. Anti-apoptotic regulation by Hepatitis C Virus Core protein through Up-regulation of Inhibitor of Caspase activated Dnase. Virology. 2003;317:24-35.

107. Ijichi H, Otsuka M, Tateishi K, Ikenoue T, Kawakami T, Kanai F, Arakawa Y, Seki N, Shimizu K, Miyazono K, Kawabe T, Omata M. Smad4-independent regulation of p21/WAF1 by transforming growth factor-b. Oncogene. 2004;23:1043-51.

108. Otsuka M*, Arai M*, Mori M*, Kato M, Kato N, Yokosuka O, Ochiai T, Takiguchi M, Omata M, Seki N. (*; equally contributed) Comparing gene expression profiles in human liver, gastric, and pancreatic tissues using full-length-enriched cDNA libraries. Hepatol Res. 2003;27:76-82.

109. Moriyama M, Hoshida Y, Otsuka M, Nishimura S, Kato N, Goto T, Taniguchi H, Shiratori Y, Seki N, Omata M. Relavance Network Between Chemosensitivity and Transcriptome in Human Hepatoma Cells. Mol Cancer Ther. 2003;2:199-205.

110. Hoshida Y, Moriyama M, Otsuka M, Kato N, Goto T, Taniguchi H, Shiratori Y, Seki N, Omata M. Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells. J Gastroenterol. 2002;37:92-5.

111. 51.  Goto T, Kato N, Yoshida H, Otsuka M, Moriyama M, Shiratori Y, Koike K, Matsumura M, Omata M. Synergistic activation of the serum response element-dependent pathway by hepatitis B virus x protein and large-isoform hepatitis delta antigen. J Infect Dis. 2003;187:820-8.

112. Otsuka M, Aizaki H, Kato N, Suzuki T, Miyamura T, Omata M, Seki N. Differential cellular gene expression induced by hepatitis B and C viruses. Biochem Biophys Res Commun.2003;300:443-7.

113. Wang Y, Kato N, Hoshida Y, Yoshida H, Taniguchi H, Goto T, Moriyama M, Otsuka M, Shiina S, Shiratori Y, Ito Y, Omata M. Interleukin-1beta Gene Polymorphisms Associated with Hepatocellular Carcinoma in Hepatitis C Virus Infection. Hepatology. 2003;37:65-71.

114. Aizaki H, Harada T, Otsuka M, Seki N, Matsuda M, Li YW, Kawakami H, Matsuura Y, Miyamura T, Suzuki T. Expression profiling of liver cell lines expressing entire- or parts of hepatitis C virus open reading frame. Hepatology. 2002;36:1431-1438.

115. Azuma T, Takei M, Yoshikawa T, Nagasugi Y, Kato M, Otsuka M, Shiraiwa H, Sugano S, Mitamura K, Sawada S, Masuho Y, Seki N. Identification of candidate genes for Sjogren's syndrome using MRL/lpr mouse model of Sjogren's syndrome and cDNA microarray analysis. Immunol Lett. 2002;81:171-6.

116. Otsuka M, Kato N, Taniguchi H, Yoshida H, Goto T, Shiratori Y, Omata M. Hepatitis C Virus Core Protein Inhibits Apoptosis via Enhanced Bcl-x(L) Expression.Virology. 2002;296:84-93.

117. Akanuma M, Maeda S, Ogura K, Mitsuno Y, Hirata Y, Ikenoue T, Otsuka M, Watanabe T, Yamaji Y, Yoshida H, Kawabe T, Shiratori Y, Omata M. The evaluation of putative virulence factors of Helicobacter pylori for gastroduodenal disease by use of a short-term Mongolian gerbil infection model. J Infect Dis. 2002;185:341-7.

118. Otsuka M, Kato M, Yoshikawa T, Chen H, Brown EJ, Masuho Y, Omata M, Seki N. Differential expression of the L-plastin gene in human colorectal cancer progression and metastasis. Biochem Biophys Res Commun. 2001;289:876-81.

119. Maeda S, Otsuka M, Hirata Y, Mitsuno Y, Yoshida H, Shiratori Y, Masuho Y, Muramatsu M, Seki N, Omata M. cDNA microarray analysis of Helicobacter pylori-mediated alteration of gene expression in gastric cancer cells. Biochem Biophys Res Commun. 2001;284:443-9.

120. Yoshida H, Kato N, Shiratori Y, Otsuka M, Maeda S, Kato J, Omata M. Hepatitis C virus core protein activates nuclear factor kappa B-dependent signaling through tumor necrosis factor receptor-associated factor. J Biol Chem. 2001;276:16399-405.

121. Goto T, Kato N, Ono-Nita SK, Yoshida H, Otsuka M, Shiratori Y, Omata M. Large isoform of hepatitis delta antigen activates serum response factor-associated transcription. J Biol Chem. 2000;275:37311-6.

122. Otsuka M, Kato N, Lan K, Yoshida H, Kato J, Goto T, Shiratori Y, Omata M. Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability. J Biol Chem. 2000;275:34122-30.

123. Kato N, Yoshida H, Kioko Ono-Nita S, Kato J, Goto T, Otsuka M, Lan K, Matsushima K, Shiratori Y, Omata M. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology. 2000;32:405-12.

Review Articles

1. Seimiya T, #Otsuka M, Fujishiro M. Overcoming T-cell exhaustion: New therapeutic targets in HCC immunotherapy. Hepatology. 2023 Oct 1;78(4):1009-1011

2. Suzuki T, #Otsuka M, Seimiya T, Iwata T, Kihsikawa T, Koike K. The biological role of metabolic reprogramming in pancreatic cancer. MedComm. 2020; 1:302-310.

3. Seimiya T, #Otsuka M, Iwata T, Shibata C, Tanaka E, Suzuki T, Koike K. Emerging roles of exosomal circular RNAs in cancer. Front Cell Dev Biol. 2020; 8:568366.

4. Sekiba K, Otsuka M, Koike K. Potential of HBx gene for hepatocarcinogenesis in non-cirrhotic liver. Semin Liver Dis. 2020 in press.

5. #Otsuka M and Koike K. Should level of HBV-RNA be used to determine when patients should stop treatment with nucleos(t)ide analogues. Clin Gastroenterol Hepatol. 2020;18(3):551-552.

6. Seimiya T, #Otsuka M, Iwata T, Tanaka E, Suzuki T, Sekiba K, Yamagami M, Ishibashi R, Koike K. Inflammation and de-differentiation in pancreatic carcinogenesis. World J Clin Cases. 2018;6(15):882-891.

7. Seimiya T, #Otsuka M, Yin LH, SUzuki T, Sekiba K, Yamagami M, Tanaka E, Ishibashi R, Koike K. Circular RNA and exosomes in pancreatic cancer progression. Transl Can Res. 2018;7(Suppl 7): S745-47

8. #Otsuka M, Tanaka E, Sekiba K, Seimiya T, Yamagami M, Koike K. MicroRNA-7: A potent suppressor of the malignant potential of hepatocellular carcinoma. Non-coding RNA Investig. 2018;2:30.

9. Sekiba K, #Otsuka M, Ohno M, Yamagami M, Kishikawa T, Suzuki T, Ishibashi R, Seimiya T, Tanaka E, Koike K. HBV pathogenesis: Fresh insights into HBV RNA. World J Gastroetenrol. 2018;24(21):2261-2268.

10. #Otsuka M, Ishibashi R, Tanaka E, Seimiya T, Suzuki T, Sekiba K, Yamagami M, Ohno M, Kishikawa T, Koike K. A tiny but crucial player bridging microbes and colonic carcinogenesisTransl Cancer Res. in press.

11. #Otsuka M, Kishikawa T, Yoshikawa T, Yamagami M, Ohno M, Takata A, Shibata C, Ishibashi R, Koike K. MicroRNAs and liver disease J Hum Genet.2016;62(1):75-80.

12. Kishikawa T, #Otsuka M, Ohno M, Yoshikawa T, Takata A, Koike K. Circulating RNAs as new biomarkers for detecting pancreatic cancer World J Gastroenterol. 2015 Jul 28;21(28):8527-40.

13. Ohno M, #Otsuka M, Kishikawa T, Yoshikawa T, Takata A, Koike K. Novel therapeutic approaches for hepatitis B virus cccDNA World J Gastroenterol. 2015;21(23):7084-8.

14. Shibata C, #Otsuka M, Kishikawa T, Ohno M, Yoshikawa T, Takata A, Koike K. Diagnostic and therapeutic application of noncoding RNAs for hepatocellular carcinoma. World J Hepatol. 2015;7(1):1-6.

15. #Otsuka M, Kishikawa T, Yoshikawa T, Ohno M, Takata A, Shibata C, Koike K. The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects. J Gastroenterol. 2014 Feb;49(2):173-84.

16. Shibata C, #Otsuka M, Kishikawa T, Yoshikawa T, Ohno M, Takata A, Koike K. Targeting microRNAs as novel therapeutics against hepato-gastrointestinal diseases. Mol and Cell Ther. 2013,1:5.

17. Takata A, #Otsuka M, Yoshikawa T, Kishikawa T, Ohno M, Koike K. MicroRNAs and liver function. Minerva Gastroenterologica e Dietologica. 2013 Jun;59(2):187-203.

18. Otsuka M, Kato N, Taniguch H, Yoshida H, Shiratori Y, Omata M. Signals induced by HCV Proteins. Frontiers in Hepatology (HCV/Oxidative Stress and Liver Diseas)  K. Okita  Edts. (2003)

19. Otsuka M, Hoshida Y, Kato N, Moriyama M, Taniguchi H, Arai M, Mori M, Seki N, Omata M. Liver chip and gene shaving. J Gastroenterol. 2003;38 Suppl 15:89-92.